FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
J Urol - 3 weeks (NewC2)
|
infigratinib Sensitive: C2 – Inclusion Criteria
J Urol - 3 weeks - (New C3)
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
erdafitinib Sensitive: A1 - Approval
|
erdafitinib Sensitive: A1 - Approval
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
BAY 1163877 Sensitive: B - Late Trials
|
BAY 1163877 Sensitive: B - Late Trials
|
FGFR3 mutation
|
Cholangiocarcinoma
|
FGFR3 mutation
|
Cholangiocarcinoma
|
erdafitinib Sensitive: C1 - Off-label
|
erdafitinib Sensitive: C1 - Off-label
|
FGFR3 mutation
|
Gastric Cancer
|
FGFR3 mutation
|
Gastric Cancer
|
erdafitinib Sensitive: C1 - Off-label
|
erdafitinib Sensitive: C1 - Off-label
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
FGFR3 mutation
|
Bladder Cancer
|
FGFR3 mutation
|
Bladder Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR3 mutation
|
Breast Cancer
|
FGFR3 mutation
|
Breast Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
FGFR3 mutation
|
NSCLC
|
FGFR3 mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
FGFR3 mutation
|
NSCLC
|
FGFR3 mutation
|
NSCLC
|
nintedanib Sensitive: C3 – Early Trials
|
nintedanib Sensitive: C3 – Early Trials
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
B-701 Sensitive: C3 – Early Trials
|
B-701 Sensitive: C3 – Early Trials
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
enfortumab vedotin Resistant: C3 – Early Trials
|
enfortumab vedotin Resistant: C3 – Early Trials
|
FGFR3 mutation
|
Solid Tumor
|
FGFR3 mutation
|
Solid Tumor
|
CPL304110 Sensitive: D – Preclinical
|
CPL304110 Sensitive: D – Preclinical
|
FGFR3 mutation
|
Endometrial Cancer
|
FGFR3 mutation
|
Endometrial Cancer
|
infigratinib Sensitive: D – Preclinical
|
infigratinib Sensitive: D – Preclinical
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
dasatinib + infigratinib Sensitive: D – Preclinical
|
dasatinib + infigratinib Sensitive: D – Preclinical
|